We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+4.69%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$15.2B
AUM Growth
+$1.14B
Cap. Flow
+$754M
Cap. Flow %
4.96%
Top 10 Hldgs %
15.87%
Holding
1,269
New
352
Increased
317
Reduced
269
Closed
320

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$124M
2
TXN icon
Texas Instruments
TXN
+$113M
3
UNH icon
UnitedHealth
UNH
+$106M
4
PM icon
Philip Morris
PM
+$106M
5
TJX icon
TJX Companies
TJX
+$93.3M

Sector Composition

Rank Sector Weight
1 Healthcare 19.99%
2 Consumer Discretionary 12.3%
3 Technology 11.57%
4 Communication Services 10.98%
5 Financials 9.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
YHOO
251
DELISTED
Yahoo Inc
YHOO
$14.5M 0.1%
373,851
+110,468
+42% +$4.53M
CNC icon
252
Centene
CNC
$31.3B
$14.4M 0.09%
509,198
+368,502
+262% +$10.9M
NVO
253
Novo Nordisk
NVO
$216B
$14.2M 0.09%
793,448
+436,840
+122% +$7.92M
GILD icon
254
Gilead Sciences
GILD
$161B
$14.2M 0.09%
198,367
-355,427
-64% -$26.4M
LYV icon
255
Live Nation Entertainment
LYV
$41.2B
$14.1M 0.09%
531,555
-339,476
-39% -$9.34M
WSO icon
256
Watsco Inc
WSO
$14.9B
$13.8M 0.09%
93,395
+48,191
+107% +$6.98M
ECL icon
257
Ecolab
ECL
$75.6B
$13.6M 0.09%
+116,236
New +$13.6M
ARCH
258
DELISTED
Arch Resources, Inc.
ARCH
$13.6M 0.09%
+174,388
New +$13.2M
NBIX icon
259
Neurocrine Biosciences
NBIX
$17.7B
$13.6M 0.09%
351,582
+141,893
+68% +$6.42M
SYY icon
260
Sysco
SYY
$39.7B
$13.5M 0.09%
244,344
-110,140
-31% -$5.72M
GMED icon
261
Globus Medical
GMED
$10.4B
$13.5M 0.09%
544,217
+522,870
+2,449% +$11.9M
PCTY icon
262
Paylocity
PCTY
$6.71B
$13.5M 0.09%
449,575
+228,816
+104% +$8.52M
FCN icon
263
FTI Consulting
FCN
$4.82B
$13.5M 0.09%
298,526
+130,799
+78% +$5.69M
SEIC icon
264
SEI Investments
SEIC
$11.9B
$13.3M 0.09%
268,984
+41,362
+18% +$1.93M
MHK icon
265
Mohawk Industries
MHK
$6.9B
$13.2M 0.09%
66,193
+4,276
+7% +$840K
PH icon
266
Parker-Hannifin
PH
$125B
$13.2M 0.09%
+94,202
New +$12.5M
TBPH icon
267
Theravance Biopharma
TBPH
$874M
$13M 0.09%
408,880
+329,812
+417% +$10.2M
PFGC icon
268
Performance Food Group
PFGC
$17.5B
$13M 0.09%
+540,213
New +$12.8M
LKQ icon
269
LKQ Corp
LKQ
$6.58B
$12.9M 0.09%
422,118
+311,231
+281% +$10.2M
WCIC
270
DELISTED
WCI Communities, Inc.
WCIC
$12.9M 0.08%
+550,000
New +$12.8M
TSRO
271
DELISTED
TESARO, Inc.
TSRO
$12.9M 0.08%
95,713
-18,149
-16% -$2.29M
TFX icon
272
Teleflex
TFX
$5.85B
$12.8M 0.08%
+79,626
New +$12.4M
NEE icon
273
NextEra Energy
NEE
$187B
$12.8M 0.08%
429,448
+413,232
+2,548% +$12.3M
OMC icon
274
Omnicom Group
OMC
$22.7B
$12.7M 0.08%
149,782
+124,210
+486% +$10.4M
GIMO
275
DELISTED
Gigamon Inc.
GIMO
$12.7M 0.08%
+279,673
New +$14.6M

Similar funds

Marshall Wace's Q4 2016 Portfolio in Review

As of Q4 2016, Marshall Wace held 1,269 positions worth $15.2B, up 8.1% from $14.1B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Marshall Wace deployed $754M of net new capital in Q4 2016, opening 352 new positions and adding to 317 existing holdings. Its largest new stake was Texas Instruments: 1,581,130 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Zoetis, an estimated $221M trimmed.

  • Marshall Wace's largest Q4 2016 buy was Texas Instruments: 1,581,130 shares worth $115M.
  • Marshall Wace added most to Amazon in Q4 2016, an estimated $124M increase.
  • Marshall Wace's biggest Q4 2016 reduction was Zoetis, cutting an estimated $221M.
  • Marshall Wace fully exited iShares MSCI Emerging Markets ETF in Q4 2016, selling an estimated $240M.
  • Marshall Wace's ten largest holdings make up 16% of its $15.2B portfolio in Q4 2016.
  • Marshall Wace opened 352 new positions and closed 320 in Q4 2016.
  • Marshall Wace's portfolio value rose 8.1% quarter-over-quarter to $15.2B.

Based on Marshall Wace's 13F filing for Q4 2016, filed 10 Feb 2017.